The DOI matches its Crossref record.
Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
Open accessAbstract
Purpose: To analyze the prognostic impact of immunophenotyping in patients with multiple myeloma (MM). Patients and Methods: We have prospectively analyzed the prognostic impact of antigenic markers, assessed by multiparametric flow cytometry, in a series of 685 newly diagnosed MM patients that were uniformly treated according to the GEM 2000 protocol. Results: Our results show that expression of both CD19 and CD28 as well as the absence of CD117 were associated with a significantly shorter progression free-survival (PFS) and overall survival (OS). Interestingly, the CD28 expression correlated with t(14;16) and del(17p), while CD117-negative patients were associated with t(4;14) and del(13q). Simultaneous assessment of CD28 and CD117 antigens allowed stratification of patients with MM into three risk categories: poor risk (CD28 positive CD117 negative), intermediate (either both markers negative or both positive), and good risk (CD28 negative CD117 positive), with PFS rates of 30, 37, and 45 months, respectively (P = .01), and OS rates of 45, 68, and not reached, respectively (P = .0001). Conclusion: To the best of our knowledge, this is the first prospective analysis in which the prognostic impact of a relatively high number of antigenic markers has been simultaneously analyzed in a large series of uniformly treated patients, showing that the expression of several antigens (particularly CD28 and CD117) on bone marrow plasma cells from patients with MM can help to identify patients at high risk of progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationon behalf of the EuroFlow Consortium (EU-FP6, L.-C.-2.-0., van Dongen, J. J. M., Lhermitte, L., Böttcher, S., Almeida, J., van der Velden, V. H. J., Flores-Montero, J., Rawstron, A., Asnafi, V, Lécrevisse, Q., et al. (2012) · Leukemia · doi:10.1038/leu.2012.120 · Cited by 934
Self-citationPaiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J. J., Montalbán, M. A., Sureda, A., Montejano, L., Gutiérrez, N. C., de Coca, A. G., et al. (2008) · Blood · doi:10.1182/blood-2008-05-159624 · Cited by 477
Self-citationChu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Yan, Z., Cao, J., Cheng, H., Qiao, J., Zhang, H., Wang, Y., Shi, M., Lan, J., Fei, X., Jin, L., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30115-2 · Cited by 315
Metadata
- Authors
- Mateo, G., Montalbán, M. A., Vidriales, M.-B., Lahuerta, J. J., Mateos, M. V., Gutiérrez, N., Rosiñol, L., Montejano, L., Bladé, J., Martínez, R., de la Rubia, J., Diaz-Mediavilla, J., Sureda, A., Ribera, J. M., Ojanguren, J. M., de Arriba, F., Palomera, L., Terol, M. J., Orfao, A., & San Miguel, J. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-06-01
- Volume
- 26
- Issue
- 16
- Pages
- 2737-2744
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2168812273
- Cited by
- 208
- References
- 0
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy. https://app.cochat.ai/papers/10.1200/jco.2007.15.4120
- The paper
- Mateo, G., Montalbán, M. A., Vidriales, M.-B., Lahuerta, J. J., Mateos, M. V., Gutiérrez, N., Rosiñol, L., Montejano, L., Bladé, J., Martínez, R., de la Rubia, J., Diaz-Mediavilla, J., Sureda, A., Ribera, J. M., Ojanguren, J. M., de Arriba, F., Palomera, L., Terol, M. J., Orfao, A., & San Miguel, J. F. (2008). Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.4120
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.